CN114470235A - Application of bismuth-based metal organic framework material as light-operated drug carrier - Google Patents
Application of bismuth-based metal organic framework material as light-operated drug carrier Download PDFInfo
- Publication number
- CN114470235A CN114470235A CN202210056615.0A CN202210056615A CN114470235A CN 114470235 A CN114470235 A CN 114470235A CN 202210056615 A CN202210056615 A CN 202210056615A CN 114470235 A CN114470235 A CN 114470235A
- Authority
- CN
- China
- Prior art keywords
- drug
- bismuth
- based metal
- light
- organic framework
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses an application of a bismuth-based metal organic framework material as a light-operated drug carrier, and an application of SU-101 as a light-operated drug carrier, wherein a drug molecule and carbonyl oxygen in the SU-101 form a hydrogen bond, so that the drug carrier has higher drug loading capacity, in addition, the electronic structure of the drug molecule can be changed by illumination, the electron cloud density of the carbonyl oxygen in the SU-101 is reduced, and further, the hydrogen bond between the drug molecule and the SU-101 carbonyl is broken, so that the light-operated drug release is realized, and the control of the drug release amount can be realized by adjusting the illumination time and the light wavelength.
Description
Technical Field
The invention belongs to the technical field of drug carriers, and particularly relates to an application of a bismuth-based metal organic framework material as a light-operated drug carrier.
Background
The statements herein merely provide background information related to the present disclosure and may not necessarily constitute prior art.
Drug therapy is still the main method of clinical treatment at present, generally, the traditional administration method needs regular administration, and the nonspecific distribution of the drug in the body can cause the problems of high dosage, fast clearance, great side effect and the like.
The existing drug carrier materials are mainly divided into inorganic materials (zeolite, Fe)3O4Mesoporous silica and gold nanomaterials) and organic materials (liposomes, micelles, gels and vesicles), however, these materials have the problems of poor stability, uncontrolled release, poor biocompatibility, etc., which limits their wide application. In recent years, scientists have developed the idea of using porous metal-organic framework Materials (MOFs) as ideal controllable drug carriers. Stimuli currently available for controlled release of drugs mainly include chemicals (pH, glucose or presence of specific enzymes), light, heat, magnetism, ultrasound and mechanical forces, all of which can be used to control the drug delivery rate of biological materials. Each stimulus can be simply and accurately controlled from the outside or internally as a stimulus for drug release. There is currently no viable solution to using light as a stimulus controllable drug carrier.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide the application of a bismuth-based metal organic framework material as a light-operated drug carrier.
In order to achieve the purpose, the invention is realized by the following technical scheme:
in a first aspect, the invention provides the use of a bismuth-based metal-organic framework material as a light-operated drug carrier.
In a second aspect, the invention provides a drug carrier comprising the bismuth-based metal organic framework material.
In a third aspect, the invention provides a light-operated release medicine, which comprises a bismuth-based metal organic framework material and a medicine loaded on the bismuth-based metal organic framework material.
In a fourth aspect, the present invention provides a method for adsorbing a drug, comprising the steps of: adding the bismuth-based metal organic framework material and/or the drug carrier into the drug solution for adsorption, and after adsorption is finished, carrying out solid-liquid separation.
In a fifth aspect, the present invention provides a device for optically controlled drug release, comprising: a bismuth-based metal organic framework loaded with a drug and an illumination device.
The above one or more embodiments of the present invention achieve the following advantageous effects:
the application of the bismuth-based metal organic framework material as a light-operated drug carrier is disclosed for the first time, as the drug molecules and carbonyl oxygen in the bismuth-based metal organic framework material form hydrogen bonds, the bismuth-based metal organic framework material has higher drug loading capacity, in addition, the electronic structure of the bismuth-based metal organic framework material can be changed by illumination, the electron cloud density of the carbonyl oxygen in the bismuth-based metal organic framework material is reduced, and further, the hydrogen bonds between the drug molecules and the carbonyl of the bismuth-based metal organic framework material are broken, so that the release of the light-operated drug is realized, and the control of the release amount of the drug can be realized by adjusting the illumination time and the light wavelength.
The light can be applied remotely with extremely high spatial and temporal accuracy, and in addition, a wide range of parameters (wavelength, light intensity, exposure time and beam diameter) can be adjusted to modulate the amount of drug released.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, are included to provide a further understanding of the invention, and are incorporated in and constitute a part of this specification, illustrate exemplary embodiments of the invention and together with the description serve to explain the invention and not to limit the invention.
FIG. 1 is a state density diagram obtained by density-functional theory calculation of a bismuth-based metal organic framework material according to example 1 of the present invention, wherein a is TDOS and PDS of different atoms, and b is TDOS and PDS of different oxygen atoms;
FIG. 2 is a graph showing the results of the verification of the adsorption effect on ciprofloxacin in example 2 of the present invention;
fig. 3 is a graph showing the result of verifying the optically controlled release effect of ciprofloxacin in example 3, where a is the dynamic process of ciprofloxacin release under irradiation of full light (full), visible light (vis) and near infrared light (NIR), b is a graph showing the comparison of the total ciprofloxacin release under irradiation of full light (full), visible light (vis) and near infrared light (NIR), and c is a graph showing the comparison of ciprofloxacin release under irradiation of monochromatic light of different wavelengths;
FIG. 4 is a schematic diagram of the bismuth-based metal-organic framework of the present invention for drug loading and light-controlled release;
FIG. 5 is a graph showing the adsorption capacity (a) of the bismuth-based metal-organic framework material of example 4 to various drugs (CIP: ciprofloxacin, NOR: norfloxacin, TET: tetracycline, DOX: doxorubicin hydrochloride, AMO: amoxicillin) and the contrast graph (b) of the amount of various drugs released at full light.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
In a first aspect, the invention provides the use of a bismuth-based metal-organic framework material as a light-operated drug carrier.
The bismuth-based metal organic framework material is bismuth-based MOFs synthesized by taking ellagic acid as an organic ligand and bismuth acetate as a bismuth source. The preparation method comprises the following steps: the specific preparation method comprises the following steps: ellagic acid, bismuth acetate and acetic acid aqueous solution with volume fraction of 6% are stirred at room temperature for 48 hours.
The bismuth-based metal organic framework material has good chemical stability, is nontoxic and biocompatible, has particle size suitable for intravenous administration and has photosensitivity, drug molecules can form hydrogen bonds with carbonyl oxygen in the bismuth-based metal organic framework material, the drug adsorption capacity is improved, in addition, the electronic structure of the bismuth-based metal organic framework material can be adjusted by light, the electron cloud density of the carbonyl oxygen is reduced, the hydrogen bonds between the carbonyl oxygen and the drug molecules are broken, and therefore, the bismuth-based metal organic framework material is suitable for being used as a light-controlled drug carrier.
The bismuth-based metal organic framework material is applied as a light-operated drug carrier, has higher drug loading capacity, can control drug release by illumination, can adjust the drug release amount by changing illumination time and wavelength, and has a schematic diagram of drug loading and light-operated drug release as shown in figure 4.
In some embodiments, the drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin.
In a second aspect, the invention provides a drug carrier comprising the bismuth-based metal organic framework material.
In a third aspect, the present invention provides a light-controlled release pharmaceutical, characterized in that: comprises a bismuth-based metal organic framework material and a drug loaded on the bismuth-based metal organic framework material;
preferably, the drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin;
preferably, the medicament is ciprofloxacin, norfloxacin or doxorubicin hydrochloride;
more preferably, the drug is ciprofloxacin or norfloxacin.
In a fourth aspect, the present invention provides a method for adsorbing a drug, comprising the steps of: adding the bismuth-based metal organic framework material and/or the drug carrier into the drug solution for adsorption, and after adsorption is finished, carrying out solid-liquid separation.
In some embodiments, the drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin;
preferably, the medicament is ciprofloxacin, norfloxacin or doxorubicin hydrochloride;
more preferably, the drug is ciprofloxacin or norfloxacin.
In some embodiments, the drug adsorption process is stirred adsorption in the dark.
Further, the concentration of the medicine solution is 2.5-20 mg/L.
Further, the mass percentage of the bismuth-based metal organic framework material and/or the drug carrier added into the drug solution is 0.02-0.07%.
In some embodiments, the temperature of the drug solution is 15-25 ℃.
In a fifth aspect, the present invention provides a device for optically controlled drug release, comprising: a bismuth-based metal organic framework loaded with a drug and an illumination device.
In some embodiments, the illumination device is an all-light source or a monochromatic light source.
The technical solution of the present invention will be described below with specific examples. The starting materials used in the following examples are all commercially available.
Example 1
And (4) theoretical calculation:
DFT calculations were performed using the Vienna de novo calculation simulation software package (VASP) and the frozen nodule full electron projection enhanced wave (PAW) method. Exchange and correlation potentials were described using Perew-Burke-Ernzehf (PBE) for Generalized Gradient Approximation (GGA). The cut-off energy of the plane wave basis set was set to 450 eV. Monkhorst-Pack k-point sampling was set to 1X 3 using primary cell C28Bi4O 26. Geometric optimization is performed until the force on each ion is reduced to
The following. The resulting structure is used to compute an electronic structure.
The electronic structure of SU-101 (as shown in fig. 1) is revealed by calculating the total state density (TDOS) and the local state density (PDOS). As can be seen from the TDOS graph, the band gap of Bi-MBA is calculated to be 1.6eV, which is slightly smaller than the test result of ultraviolet-visible diffuse reflection analysis. From PDOS plots, it can be seen that the Bi atom contributes little to the boundary orbital, whereas the broad valence and conduction bands in the organic ligand are both composed primarily of O and C atoms. Furthermore, through studies of PDOS on different oxygen atoms, it was found that O3 (oxygen atom in carbonyl group) contributes only to the valence band, while the other oxygen atoms O2 and O4 contribute not only to the valence band but also to the conduction band. While O1 and O5 contribute less to the conduction and valence bands. This means that the electron cloud density of O3 decreases under illumination, which is the reason for hydrogen bond cleavage.
Example 2
Ciprofloxacin drug adsorption:
bismuth-based Metal-organic framework Material (SU-101) (25mg) powder was added to ciprofloxacin aqueous solution (50mL,10mg/L), stirred in the dark, and the adsorption process was performed at room temperature (25 ℃). During the adsorption, 1.5mL of suspension was taken out every 30 min. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
In the embodiment, SU-101 is used as a drug carrier of ciprofloxacin, has the highest adsorption amount on a 10mg/L ciprofloxacin solution, reaches adsorption-desorption equilibrium within 3 hours, and reaches 71 percent of adsorption amount, as shown in FIG. 2.
Example 3
Light controlled ciprofloxacin drug release
1. Full-light drug release test
SU-101(25mg) powder was added to ciprofloxacin aqueous solution (50mL,10mg/L), stirred in the dark for 3h to establish adsorption and desorption equilibrium, and the adsorption was carried out at room temperature (25 ℃). A300 watt xenon arc lamp was used as the light source, and 1.5mL of the suspension was removed every 30 min. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
2. Drug release test under visible light
SU-101(25mg) powder was added to ciprofloxacin aqueous solution (50mL,10mg/L), stirred in the dark for 3h to establish adsorption and desorption equilibrium, and the adsorption was carried out at room temperature (25 ℃). A300W xenon arc lamp equipped with a 420nm cut-off filter was used as the light source, and 1.5mL of the suspension was taken out every 30 min. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
3. Drug release experiment under near infrared light
SU-101(25mg) powder was added to ciprofloxacin aqueous solution (50mL,10mg/L), stirred in the dark for 3h to establish adsorption and desorption equilibrium, and the adsorption was carried out at room temperature (25 ℃). A300-watt xenon arc lamp equipped with an 800nm cut-off filter was used as the light source, and 1.5mL of the suspension was taken out every 30 min. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
4. Drug release experiment under monochromatic light
SU-101(25mg) powder was added to ciprofloxacin aqueous solution (50mL,10mg/L), stirred in the dark for 3h to establish adsorption and desorption equilibrium, and the adsorption was carried out at room temperature (25 ℃). Using a 5w monochromator (which can produce monochromatic light of 365nm, 385nm, 420nm, 450nm, 485nm, 520nm, 595nm and 630 nm) as a light source, 1.5mL of the suspension was taken out every 30 min. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
In this example, it is found through experiments that the release amount of ciprofloxacin under the all light condition is the highest, and reaches 95.56%, the release amount of visible light is 36.36%, and almost no ciprofloxacin is released under the near-infrared light, and further, monochromatic light with different wavelengths is used to perform a drug release experiment, and it is found that the influence of light with different wavelengths on the drug release amount is consistent with the light absorption capability of SU-101 (as shown in c in fig. 3).
Example 4
Adsorption experiments of five drugs:
five parts of bismuth-based metal organic framework material (SU-101) (25mg) powder are respectively added into ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride and amoxicillin aqueous solutions (50mL, 15mg/L), stirred in the dark, the adsorption process is carried out at room temperature (28 ℃), and after stirring and adsorption for 3 hours, 1.5mL of suspension is taken out of each medicine aqueous solution. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
Full light drug release experiments for five drugs:
five parts of bismuth-based metal organic framework material (SU-101) (25mg) powder are respectively added into an aqueous solution (50mL, 9mg/L) of ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride and amoxicillin, stirred for 3 hours in the dark to establish adsorption and desorption equilibrium, and the adsorption process is carried out at room temperature (22 ℃).
After the adsorption was completed, a 300 watt xenon arc lamp was used as a light source, and 1.5mL of each suspension of the drug solution was taken out every 30 min. After centrifugation, the solution was examined for absorbance change at 270nm using an ultraviolet-visible spectrophotometer (UV-2550, Shimadzu).
FIG. 5 is a comparison graph (b) showing the adsorption capacity (a) of the bismuth-based metal-organic framework material to different drugs (CIP: ciprofloxacin, NOR: norfloxacin, TET: tetracycline, DOX: doxorubicin hydrochloride, AMO: amoxicillin) and the release amount of different drugs at full light. As can be seen from FIG. 5, the adsorption rate of the bismuth-based metal organic framework material to ciprofloxacin can reach 85.8%, and the total light drug release rate reaches 95.56%; the absorption rate of norfloxacin can reach 91 percent, and the release rate of all-optical drugs can reach 95.45 percent; the highest adsorption rate to amoxicillin is 27.9 percent, and the total light drug release rate reaches 100 percent; the highest adsorption rate to tetracycline is 23.2%, and the full-light drug release rate reaches 100%; the highest adsorption rate to doxorubicin hydrochloride is 91%, and the highest all-optical drug release rate is 78%.
Therefore, the bismuth-based metal organic framework material has good adsorption and light-operated release rates on ciprofloxacin and norfloxacin, and has a slightly poor light-operated release rate on doxorubicin hydrochloride.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The application of bismuth-based metal organic framework material as light-operated drug carrier.
2. Use according to claim 1, characterized in that: such drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin;
preferably, the medicament is ciprofloxacin, norfloxacin or doxorubicin hydrochloride;
more preferably, the drug is ciprofloxacin or norfloxacin.
3. A drug carrier characterized by: comprises a bismuth-based metal organic framework material.
4. A light-controlled release pharmaceutical, characterized by: comprises a bismuth-based metal organic framework material and a drug loaded on the bismuth-based metal organic framework material;
preferably, the drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin;
preferably, the medicament is ciprofloxacin, norfloxacin or doxorubicin hydrochloride;
more preferably, the drug is ciprofloxacin or norfloxacin.
5. A method of drug adsorption characterized by: the method comprises the following steps: adding the bismuth-based metal organic framework material and/or the drug carrier into the drug solution for adsorption, and after adsorption is finished, carrying out solid-liquid separation.
6. The drug adsorption method of claim 5, wherein: such drugs include, but are not limited to, ciprofloxacin, norfloxacin, tetracycline, doxorubicin hydrochloride, and amoxicillin.
7. The drug adsorption method of claim 5, wherein: the drug adsorption process is stirring adsorption in the dark.
8. The drug adsorption method of claim 5, wherein: the concentration of the medicine solution is 2.5-20 mg/L;
further, the mass percentage of the bismuth-based metal organic framework material and/or the drug carrier added into the drug solution is 0.02-0.07%;
further, the temperature of the drug solution is 15-25 ℃.
9. A device for optically controlled drug release, comprising: the method comprises the following steps: a bismuth-based metal organic framework loaded with a drug and an illumination device.
10. The method for light controlled drug release of claim 9, wherein: the illumination device is a full-light source or a monochromatic light source.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210056615.0A CN114470235B (en) | 2022-01-18 | 2022-01-18 | Application of bismuth-based metal organic framework material as light-operated drug carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210056615.0A CN114470235B (en) | 2022-01-18 | 2022-01-18 | Application of bismuth-based metal organic framework material as light-operated drug carrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114470235A true CN114470235A (en) | 2022-05-13 |
| CN114470235B CN114470235B (en) | 2023-05-30 |
Family
ID=81472097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210056615.0A Active CN114470235B (en) | 2022-01-18 | 2022-01-18 | Application of bismuth-based metal organic framework material as light-operated drug carrier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470235B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984254A (en) * | 2022-06-08 | 2022-09-02 | 上海交通大学医学院附属第九人民医院 | Photoacoustic imaging contrast agent and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770893A (en) * | 2014-12-17 | 2016-07-20 | 中国科学院宁波材料技术与工程研究所 | Bismuth-based composite nano-material, and tumor diagnosis and treatment application thereof |
| CN106540750A (en) * | 2016-10-21 | 2017-03-29 | 山东大学 | With visible light-responded small numerator modified catalysis material and preparation method |
| CN107001031A (en) * | 2014-10-14 | 2017-08-01 | 芝加哥大学 | Nano particle for photodynamic therapy, the photodynamic therapy of X ray induction, radiotherapy, chemotherapy, immunotherapy and its any combination |
| US20180264033A1 (en) * | 2015-02-03 | 2018-09-20 | University Court Of The University Of St. Andrews | NO containing compositions |
| CN108619081A (en) * | 2018-05-22 | 2018-10-09 | 浙江理工大学 | A kind of photosensitive micropin and preparation method thereof, controlled release method |
| CN110787792A (en) * | 2019-11-19 | 2020-02-14 | 常州大学 | Bi with visible light response2Ti2O7-TiO2Preparation method of/RGO nano composite material |
| CN112315975A (en) * | 2020-10-30 | 2021-02-05 | 国家纳米科学中心 | Acid-responsive polymer modified bismuth elementary nanosheet carrying nucleic acid molecules and preparation method and application thereof |
| CN112521618A (en) * | 2020-10-30 | 2021-03-19 | 山东大学 | Bismuth-based metal organic framework material and preparation method and application thereof |
-
2022
- 2022-01-18 CN CN202210056615.0A patent/CN114470235B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001031A (en) * | 2014-10-14 | 2017-08-01 | 芝加哥大学 | Nano particle for photodynamic therapy, the photodynamic therapy of X ray induction, radiotherapy, chemotherapy, immunotherapy and its any combination |
| CN105770893A (en) * | 2014-12-17 | 2016-07-20 | 中国科学院宁波材料技术与工程研究所 | Bismuth-based composite nano-material, and tumor diagnosis and treatment application thereof |
| US20180264033A1 (en) * | 2015-02-03 | 2018-09-20 | University Court Of The University Of St. Andrews | NO containing compositions |
| CN106540750A (en) * | 2016-10-21 | 2017-03-29 | 山东大学 | With visible light-responded small numerator modified catalysis material and preparation method |
| CN108619081A (en) * | 2018-05-22 | 2018-10-09 | 浙江理工大学 | A kind of photosensitive micropin and preparation method thereof, controlled release method |
| CN110787792A (en) * | 2019-11-19 | 2020-02-14 | 常州大学 | Bi with visible light response2Ti2O7-TiO2Preparation method of/RGO nano composite material |
| CN112315975A (en) * | 2020-10-30 | 2021-02-05 | 国家纳米科学中心 | Acid-responsive polymer modified bismuth elementary nanosheet carrying nucleic acid molecules and preparation method and application thereof |
| CN112521618A (en) * | 2020-10-30 | 2021-03-19 | 山东大学 | Bismuth-based metal organic framework material and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ERIK SVENSSON GRAPE ET AL.: "A Robust and Biocompatible Bismuth Ellagate MOF Synthesized Under Green Ambient Conditions", 《J. AM. CHEM. SOC.》 * |
| 宋建华;钟翔;邓钏;杜亚洁;潘蕾;卫贤贤;: "溴化氧铋制备及降解不同浓度罗丹明B研究" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984254A (en) * | 2022-06-08 | 2022-09-02 | 上海交通大学医学院附属第九人民医院 | Photoacoustic imaging contrast agent and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114470235B (en) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sheng et al. | Dual roles of protein as a template and a sulfur provider: a general approach to metal sulfides for efficient photothermal therapy of cancer | |
| CN107412195B (en) | PH-responsive antitumor drug carrier material and preparation and application thereof | |
| Chen et al. | Palladium Nanocrystals‐Engineered Metal–Organic Frameworks for Enhanced Tumor Inhibition by Synergistic Hydrogen/Photodynamic Therapy | |
| CN106267204B (en) | A kind of composite material and preparation method and application of black phosphorus nanometer sheet-antitumoral compounds | |
| Wang et al. | Mini review of TiO2‐based multifunctional nanocomposites for near‐infrared light–responsive phototherapy | |
| CN109602919B (en) | Black phosphorus quantum dot coated by core-shell metal organic framework and preparation method and application thereof | |
| US20110196285A1 (en) | Hollow Mesoporous Silica Sphere Coated with Gold and Preparation Method Thereof and Use in Cancer Therapy | |
| Yu et al. | Transforming a sword into a knife: Persistent phototoxicity inhibition and alternative therapeutical activation of highly-photosensitive phytochlorin | |
| Cui et al. | Outstanding drug-loading/release capacity of hollow Fe-metal–organic framework-based microcapsules: a potential multifunctional drug-delivery platform | |
| CN105797157B (en) | A kind of preparation method and application of porous nucleocapsid bimetallic organic frame nano drug-carrying body | |
| Song et al. | Biodegradable Bismuth‐Based Nano‐Heterojunction for Enhanced Sonodynamic Oncotherapy through Charge Separation Engineering | |
| Huang et al. | Antibacterial Carbon Dots‐Based Composites | |
| CN114470235B (en) | Application of bismuth-based metal organic framework material as light-operated drug carrier | |
| CN113751079B (en) | Perovskite-titanium dioxide nano composite photocatalyst loaded by biological material and construction method and application thereof | |
| Wen et al. | Defect-rich glassy IrTe2 with dual enzyme-mimic activities for sono-photosynergistic-enhanced oncotherapy | |
| Li et al. | NIR-II-responsive CeO2–x@ HA nanotheranostics for photoacoustic imaging-guided sonodynamic-enhanced synergistic phototherapy | |
| Zhao et al. | Which is Better for Nanomedicines: Nanocatalysts or Single‐Atom Catalysts? | |
| Chang et al. | Precise Engineering of a Se/Te Nanochaperone for Reinvigorating Cancer Radio‐Immunotherapy | |
| Jia et al. | Boosting the tumor photothermal therapy with hollow CoSnSx-based injectable hydrogel via the sonodynamic and dual-gas therapy | |
| CN113509559B (en) | CO and drug release synergistic therapeutic agent and preparation method and application thereof | |
| CN115581777A (en) | Preparation method and application of AuNC @ ZIF-8 drug carrier | |
| CN102276496A (en) | Aceglutamide compound and medicinal composition thereof | |
| WO2023082219A1 (en) | Method for efficiently preparing nano-composite material in which metal-organic framework is loaded with selenium atoms and use thereof | |
| CN113855815B (en) | Zinc-containing metal organic framework coated manganese dioxide nanocomposite and preparation and application thereof | |
| Trofimova et al. | The mechanism of mechanochemical interaction between amorphous silicon dioxide and pyrocatechol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |